Luis Eduardo Pino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis Eduardo Pino has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Erick Andrés Cantor
Fundación Santa Fe de Bogota
8 shared publications - Ivan Triana
Fundación Santa Fe de Bogota
8 shared publications - Javier Mauricio Segovia
Oncology Service, Fundación Santa Fe de Bogotá, Bogotá, Colombia
7 shared publications - Andrés Felipe Bejarano-Ramirez
Fundación Santa Fe de Bogota
6 shared publications - Henry Alexander Vargas
Fundación Santafé de Bogotá, Departamento de Oncología, Bogotá, Colombia. 6 Los Cobos Medical Center, Departamento de Oncología, Bogotá, Colombia
5 shared publications - Andres Felipe Cardona
Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
4 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Elsevier in SSRN Electronic Journal
Building Clinical Artificial Intelligence Units in Colombian Hospitals: A Comparative Case Study of Governance, Sandboxing, and Institutional Scale-Up
Background: Hospitals face mounting pressure to adopt artificial intelligence (AI), yet many lack an operating structure capable of separating safe innovation from unsafe deployment. Algorithmic stewardship, structured governance, and post-deployment monitoring are now institutional responsibilities, but examples from middle-income settings remain scarce. We describe two Clinical AI Units in Colombian high-complexity hospitals.Methods: Comparative institutional case study (SQUIRE 2·0) of two Clinical AI Units established between 2025 and 2026: the Unidad Clínica de Inteligencia Artificial (UCIA) at Fundación Cardioinfantil – LaCardio (Bogotá), and the Área de IA Clínica (IACL) at Hospital Militar Central (Bogotá). Implementation observations, governance documentation, intake forms, RACI matrices, and sandbox records were synthesised against international frameworks (DECIDE-AI, TRIPOD+AI, CFIR, RE-AIM, SEIPS, NASSS). No patient-level data were analysed.Findings: Across one year of embedded work, both units operationalised a dual architecture combining a medical sandbox (Route A: anonymised data, no clinical impact) and a clinical MLOps service (Route B: validated deployment with drift, bias and safety monitoring). LaCardio formalised a seven-layer, eight-phase sandbox with explicit transition gates; Hospital Militar Central formalised an institutional portfolio with documentary controls and phased scale-up. Twelve transversal actors in three responsibility tiers (strategic governance, operational coordination, specialist consultation) were defined with RACI assignments. A three-route eligibility framework (sandbox · full MLOps · third-party validation) prevented informal shadow-AI adoption. No new clinical effectiveness data are presented.Interpretation: Clinical AI implementation in middle-income hospitals requires an institutional layer between executive strategy and individual tools: a unit that governs intake, data access, validation, deployment, monitoring, and decommissioning. The dual architecture (sandbox + MLOps service) provides a replicable blueprint for trustworthy hospital AI in Colombia and similar settings.
- 4 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBuilding Clinical Artificial Intelligence Units in Colombian Hospitals: A Comparative Case Study of Governance, Sandboxing, and Institutional Scale-Up
Background: Hospitals face mounting pressure to adopt artificial intelligence (AI), yet many lack an operating structure capable of separating safe innovation from unsafe deployment. Algorithmic stewardship, structured governance, and post-deployment monitoring are now institutional responsibilities, but examples from middle-income settings remain scarce. We describe two Clinical AI Units in Colombian high-complexity hospitals.Methods: Comparative institutional case study (SQUIRE 2·0) of two Clinical AI Units established between 2025 and 2026: the Unidad Clínica de Inteligencia Artificial (UCIA) at Fundación Cardioinfantil – LaCardio (Bogotá), and the Área de IA Clínica (IACL) at Hospital Militar Central (Bogotá). Implementation observations, governance documentation, intake forms, RACI matrices, and sandbox records were synthesised against international frameworks (DECIDE-AI, TRIPOD+AI, CFIR, RE-AIM, SEIPS, NASSS). No patient-level data were analysed.Findings: Across one year of embedded work, both units operationalised a dual architecture combining a medical sandbox (Route A: anonymised data, no clinical impact) and a clinical MLOps service (Route B: validated deployment with drift, bias and safety monitoring). LaCardio formalised a seven-layer, eight-phase sandbox with explicit transition gates; Hospital Militar Central formalised an institutional portfolio with documentary controls and phased scale-up. Twelve transversal actors in three responsibility tiers (strategic governance, operational coordination, specialist consultation) were defined with RACI assignments. A three-route eligibility framework (sandbox · full MLOps · third-party validation) prevented informal shadow-AI adoption. No new clinical effectiveness data are presented.Interpretation: Clinical AI implementation in middle-income hospitals requires an institutional layer between executive strategy and individual tools: a unit that governs intake, data access, validation, deployment, monitoring, and decommissioning. The dual architecture (sandbox + MLOps service) provides a replicable blueprint for trustworthy hospital AI in Colombia and similar settings.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 83
Air pollution, driver mutations, and survival in non-small cell lung cancer: insights from a high-altitude Hispanic cohort
Background: Lung cancer remains a critical global health concern, with a substantial fraction arising in never-smokers. Air pollution—including particulate matter (PM2.5, PM10), nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O3)—has been implicated in lung carcinogenesis; however, studies linking these exposures to molecular biomarkers in Hispanic populations remain scarce. This study aimed to evaluate the association between exposure to air pollutants and oncogenic mutations in non-small cell lung cancer (NSCLC) in Hispanic patients in Bogotá. Methods: A retrospective cohort study was conducted on 205 Hispanic patients diagnosed with NSCLC between 2015 and 2022 at a quaternary care hospital in Bogotá, Colombia. Lung cancer driver mutations [epidermal growth factor receptor mutations (EGFRm), anaplastic lymphoma kinase (ALK) rearrangement, and programmed death-ligand 1 (PD-L1) expression] were assessed by reverse transcription polymerase chain reaction and immunohistochemistry. The estimated individual-level exposure to air pollutants (PM2.5, PM10, NO2, SO2, O3, and CO) was assessed from Bogotá’s Air Monitoring Stations using an inverse distance weighted regression model. Adjusted logistic regression analyses evaluated associations between biomarkers and pollutants. Kaplan-Meier and Cox proportional hazards models examined survival outcomes. Results: Mean annual exposure to PM2.5 (15.9 µg/m3), PM10 (32.6 µg/m3), and NO2 (28.3 µg/m3) exceeded the thresholds recommended by the World Health Organization. EGFRm were identified in 24.9% of patients, ALK rearrangements in 12.2%, and PD-L1 expression ≥1% in 41.5% (≥50% in 5.4%). EGFRm was associated with increased exposure to PM2.5 and PM10 levels [PM2.5: odds ratio (OR) 2.49, 95% confidence interval (CI): 1.11–6.41; PM10: OR 1.54, 95% CI: 1.05–2.34]. NO2 was associated with increased PD-L1 expression (OR 1.83, 95% CI: 1.33–2.65). The 5-year overall survival (OS) rate was 29.0%. Increased exposure to PM2.5 [hazard ratio (HR) 1.72; 95% CI: 1.04–2.84] and SO2 (HR 1.69, 95% CI: 1.07–2.68) were associated with mortality. Conclusions: These results underscore the potential impact of air pollution on the molecular landscape and clinical outcomes of patients diagnosed with NSCLC, and they open new avenues for research in genetically admixed populations.
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 83
Open AccessAir pollution, driver mutations, and survival in non-small cell lung cancer: insights from a high-altitude Hispanic cohort
Background: Lung cancer remains a critical global health concern, with a substantial fraction arising in never-smokers. Air pollution—including particulate matter (PM2.5, PM10), nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O3)—has been implicated in lung carcinogenesis; however, studies linking these exposures to molecular biomarkers in Hispanic populations remain scarce. This study aimed to evaluate the association between exposure to air pollutants and oncogenic mutations in non-small cell lung cancer (NSCLC) in Hispanic patients in Bogotá. Methods: A retrospective cohort study was conducted on 205 Hispanic patients diagnosed with NSCLC between 2015 and 2022 at a quaternary care hospital in Bogotá, Colombia. Lung cancer driver mutations [epidermal growth factor receptor mutations (EGFRm), anaplastic lymphoma kinase (ALK) rearrangement, and programmed death-ligand 1 (PD-L1) expression] were assessed by reverse transcription polymerase chain reaction and immunohistochemistry. The estimated individual-level exposure to air pollutants (PM2.5, PM10, NO2, SO2, O3, and CO) was assessed from Bogotá’s Air Monitoring Stations using an inverse distance weighted regression model. Adjusted logistic regression analyses evaluated associations between biomarkers and pollutants. Kaplan-Meier and Cox proportional hazards models examined survival outcomes. Results: Mean annual exposure to PM2.5 (15.9 µg/m3), PM10 (32.6 µg/m3), and NO2 (28.3 µg/m3) exceeded the thresholds recommended by the World Health Organization. EGFRm were identified in 24.9% of patients, ALK rearrangements in 12.2%, and PD-L1 expression ≥1% in 41.5% (≥50% in 5.4%). EGFRm was associated with increased exposure to PM2.5 and PM10 levels [PM2.5: odds ratio (OR) 2.49, 95% confidence interval (CI): 1.11–6.41; PM10: OR 1.54, 95% CI: 1.05–2.34]. NO2 was associated with increased PD-L1 expression (OR 1.83, 95% CI: 1.33–2.65). The 5-year overall survival (OS) rate was 29.0%. Increased exposure to PM2.5 [hazard ratio (HR) 1.72; 95% CI: 1.04–2.84] and SO2 (HR 1.69, 95% CI: 1.07–2.68) were associated with mortality. Conclusions: These results underscore the potential impact of air pollution on the molecular landscape and clinical outcomes of patients diagnosed with NSCLC, and they open new avenues for research in genetically admixed populations.
- Open Access
- 23 January 2026
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
- Vol. 42 (1)
Neurología en la era de la inteligencia artificial: la cognición aumentada
La neurología se caracteriza por un ejercicio clínico altamente sofisticado, basado en la semiología, la localización anatómica y la integración cuidadosa de la información clínica. Sin embargo, este modelo entra en una nueva tensión con la incorporación acelerada de la inteligencia artificial, no como una herramienta periférica, sino como una transformación que impacta directamente la cognición médica. En este contexto, aunque la inteligencia artificial ofrece capacidades relevantes como análisis de datos, apoyo diagnóstico y automatización de tareas, su adopción plantea riesgos importantes. En particular, el sesgo de automatización puede llevar a una delegación excesiva del juicio clínico, reduciendo progresivamente el estándar cognitivo del especialista. Además, en entornos como el latinoamericano, marcados por fragmentación, inequidades y limitaciones estructurales, una implementación inadecuada podría amplificar problemas existentes en lugar de resolverlos. Por ello, no toda automatización implica mejora clínica, ni todo modelo predictivo fortalece la práctica médica. Más bien, la integración tecnológica debe orientarse a liberar carga operativa sin sustituir la capacidad interpretativa del neurólogo. En consecuencia, se vuelve fundamental desarrollar alfabetización en inteligencia artificial y asumir un rol activo en su implementación, preservando el juicio clínico como eje central del acto médico.
- 23 January 2026
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
- Vol. 42 (1)
Open AccessNeurología en la era de la inteligencia artificial: la cognición aumentada
La neurología se caracteriza por un ejercicio clínico altamente sofisticado, basado en la semiología, la localización anatómica y la integración cuidadosa de la información clínica. Sin embargo, este modelo entra en una nueva tensión con la incorporación acelerada de la inteligencia artificial, no como una herramienta periférica, sino como una transformación que impacta directamente la cognición médica. En este contexto, aunque la inteligencia artificial ofrece capacidades relevantes como análisis de datos, apoyo diagnóstico y automatización de tareas, su adopción plantea riesgos importantes. En particular, el sesgo de automatización puede llevar a una delegación excesiva del juicio clínico, reduciendo progresivamente el estándar cognitivo del especialista. Además, en entornos como el latinoamericano, marcados por fragmentación, inequidades y limitaciones estructurales, una implementación inadecuada podría amplificar problemas existentes en lugar de resolverlos. Por ello, no toda automatización implica mejora clínica, ni todo modelo predictivo fortalece la práctica médica. Más bien, la integración tecnológica debe orientarse a liberar carga operativa sin sustituir la capacidad interpretativa del neurólogo. En consecuencia, se vuelve fundamental desarrollar alfabetización en inteligencia artificial y asumir un rol activo en su implementación, preservando el juicio clínico como eje central del acto médico.
- Open Access
- 10 December 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (Sp. 3) , 10-23
Advanced artificial intelligence in piRNA and PIWI-like protein research: A systematic review of recurrent neural networks, long short-term memory, and emerging computational techniques
Introduction. PIWI-interacting RNAs are small and non-coding RNAs involved in gene regulation and transposable element repression, emerging as critical biomarkers and therapeutic targets in oncology. Advances in artificial intelligence, such as recurrent neural networks, long short-term memory networks, and graph convolutional networks, offer significant improvements in PIWI-interacting RNA detection.Objectives. To evaluate the performance of artificial intelligence models, including recurrent neural networks, long short-term memory, and graph convolutional networks, in detecting PIWI-interacting RNAs and assessing their implications for cancer diagnostics and prognosis.Materials and methods. A systematic review of 24 studies was conducted across PubMed, ScienceDirect, Scopus, and Web of Science, focusing on artificial intelligence-based approaches for PIWI-interacting RNA detection. Inclusion criteria were original articles published in English or Spanish using artificial intelligence models in clinical or experimental settings. Performance metrics such as accuracy, sensitivity, and specificity were analyzed.Results. Long short-term memory models achieved the highest overall accuracy (92.3%), followed by graph convolutional networks (91.4%), support vector machines (88%), and recurrent neural networks (85.7%). Sensitivity and specificity were also highest in long short-term memory (94% and 91%, respectively). Graph convolutional networks showed superior performance in identifying PIWI-interacting RNA-disease associations with complex datasets. Support vector machine models were effective in smaller datasets but exhibited scalability limitations.Conclusion. Artificial intelligence models, especially long short-term memory and graph convolutional networks, significantly enhance PIWI-interacting RNA detection, supporting their application in cancer diagnostics and personalized medicine. Future studies should refine these models, address dataset biases, and explore their integration into clinical workflows.
- 10 December 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (Sp. 3) , 10-23
Open AccessAdvanced artificial intelligence in piRNA and PIWI-like protein research: A systematic review of recurrent neural networks, long short-term memory, and emerging computational techniques
Introduction. PIWI-interacting RNAs are small and non-coding RNAs involved in gene regulation and transposable element repression, emerging as critical biomarkers and therapeutic targets in oncology. Advances in artificial intelligence, such as recurrent neural networks, long short-term memory networks, and graph convolutional networks, offer significant improvements in PIWI-interacting RNA detection.Objectives. To evaluate the performance of artificial intelligence models, including recurrent neural networks, long short-term memory, and graph convolutional networks, in detecting PIWI-interacting RNAs and assessing their implications for cancer diagnostics and prognosis.Materials and methods. A systematic review of 24 studies was conducted across PubMed, ScienceDirect, Scopus, and Web of Science, focusing on artificial intelligence-based approaches for PIWI-interacting RNA detection. Inclusion criteria were original articles published in English or Spanish using artificial intelligence models in clinical or experimental settings. Performance metrics such as accuracy, sensitivity, and specificity were analyzed.Results. Long short-term memory models achieved the highest overall accuracy (92.3%), followed by graph convolutional networks (91.4%), support vector machines (88%), and recurrent neural networks (85.7%). Sensitivity and specificity were also highest in long short-term memory (94% and 91%, respectively). Graph convolutional networks showed superior performance in identifying PIWI-interacting RNA-disease associations with complex datasets. Support vector machine models were effective in smaller datasets but exhibited scalability limitations.Conclusion. Artificial intelligence models, especially long short-term memory and graph convolutional networks, significantly enhance PIWI-interacting RNA detection, supporting their application in cancer diagnostics and personalized medicine. Future studies should refine these models, address dataset biases, and explore their integration into clinical workflows.
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41204
PD-L1 expression in gastric cancer assessed with antibodies 28-8 and 22C3
Programmed cell death ligand 1 (PD-L1) has emerged as a key biomarker in determining both the progression and prognosis of gastric cancer (GC). Consequently, its detection through immunohistochemical (IHC) analysis is essential for guiding appropriate treatment selection. We conducted an analytical, observational study based on a five-year retrospective cohort of patients diagnosed with gastric cancer at a comprehensive oncology center in Colombia. All patients underwent immunohistochemistry (IHC) to assess PD-L1 expression and calculate the Combined Positive Score (CPS). The objective of this study was to compare the positivity detection rates between the 28-8 and 22C3 assays and to evaluate the concordance between them. A descriptive analysis of clinical and pathological variables was performed. Univariate analysis was used to determine the frequency of PD-L1 expression and CPS distribution. Kaplan-Meier survival analysis was applied and stratified by PD-L1 status. Concordance between the two assays was assessed using the kappa (κ) index. A total of 175 patients diagnosed with gastric cancer (GC) and tested for PD-L1 expression were included in the study. Complete pathological and IHC data were available for 155 patients. Among them, 39.4% were tested with the 28-8 assay, and 60.6% with the 22C3 assay. PD-L1 positivity was observed in 34.4% of cases using the 28-8 assay and in 28.7% using the 22C3 assay. Among patients with available follow-up data (n = 34), PD-L1 testing was performed using the 22C3 clone, with a positivity rate of 35.3%. In the subgroup analysis of patients tested with both antibodies (n = 20), 60% were PD-L1 positive. Within this subset, 25% had a CPS of 1-4, 16.7% had a CPS of 5-9, and 58.3% had a CPS ≥ 10. For the 22C3 assay specifically, PD-L1 positivity was observed in 40% of cases, with 37.5% having a CPS of 1-4 and 62.5% a CPS ≥ 10; notably, no cases in this group had a CPS of 5-9. The concordance rate between the 28-8 and 22C3 assays was 61%, as measured by the kappa index. The 28-8 clone identified a higher proportion of patients with PD-L1 expression compared to the 22C3 antibody. However, both assays demonstrated a concordance rate of 61%. In the study population, the subgroup with a Combined Positive Score (CPS) ≥ 10 was the most prevalent, suggesting that high PD-L1 expression is relatively common and potentially clinically relevant in this cohort.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41204
Open AccessPD-L1 expression in gastric cancer assessed with antibodies 28-8 and 22C3
Programmed cell death ligand 1 (PD-L1) has emerged as a key biomarker in determining both the progression and prognosis of gastric cancer (GC). Consequently, its detection through immunohistochemical (IHC) analysis is essential for guiding appropriate treatment selection. We conducted an analytical, observational study based on a five-year retrospective cohort of patients diagnosed with gastric cancer at a comprehensive oncology center in Colombia. All patients underwent immunohistochemistry (IHC) to assess PD-L1 expression and calculate the Combined Positive Score (CPS). The objective of this study was to compare the positivity detection rates between the 28-8 and 22C3 assays and to evaluate the concordance between them. A descriptive analysis of clinical and pathological variables was performed. Univariate analysis was used to determine the frequency of PD-L1 expression and CPS distribution. Kaplan-Meier survival analysis was applied and stratified by PD-L1 status. Concordance between the two assays was assessed using the kappa (κ) index. A total of 175 patients diagnosed with gastric cancer (GC) and tested for PD-L1 expression were included in the study. Complete pathological and IHC data were available for 155 patients. Among them, 39.4% were tested with the 28-8 assay, and 60.6% with the 22C3 assay. PD-L1 positivity was observed in 34.4% of cases using the 28-8 assay and in 28.7% using the 22C3 assay. Among patients with available follow-up data (n = 34), PD-L1 testing was performed using the 22C3 clone, with a positivity rate of 35.3%. In the subgroup analysis of patients tested with both antibodies (n = 20), 60% were PD-L1 positive. Within this subset, 25% had a CPS of 1-4, 16.7% had a CPS of 5-9, and 58.3% had a CPS ≥ 10. For the 22C3 assay specifically, PD-L1 positivity was observed in 40% of cases, with 37.5% having a CPS of 1-4 and 62.5% a CPS ≥ 10; notably, no cases in this group had a CPS of 5-9. The concordance rate between the 28-8 and 22C3 assays was 61%, as measured by the kappa index. The 28-8 clone identified a higher proportion of patients with PD-L1 expression compared to the 22C3 antibody. However, both assays demonstrated a concordance rate of 61%. In the study population, the subgroup with a Combined Positive Score (CPS) ≥ 10 was the most prevalent, suggesting that high PD-L1 expression is relatively common and potentially clinically relevant in this cohort.
- Open Access
- 23 September 2025
- Published by Asociacion Latinoamericana de Torax in Respirar
- Vol. 17 (3) , 287-296
Nueva era en el abordaje del adenocarcinoma de pulmón estadio temprano: estudio observacional con seguimiento de 3 años
Background: Lung cancer is frequently diagnosed in advanced stages and is currently the leading cause of cancer-related mortality worldwide. A multidisciplinary approach is crucial to optimize diagnosis, treatment and improve patient survival. Methods: A retrospective cohort analytical study over two time periods, including patients over 18 years old with early-stage lung adenocarcinoma treated at a high-complexity oncology center in Colombia. The exposure group (2021-2023) received multidisciplinary care, while the non-exposure group (2018-2020) was managed conventionally by individual specialists. The study aimed to compare clinical outcomes and treatment times between both groups. Statistical analysis was based on the distribution of variables. Results: A total of 34 patients were included. The multidisciplinary approach enabled earlier diagnosis of lung adenocarcinoma, increasing early-stage identification from 30% to 61% between 2018 and 2022. Additionally, the multidisciplinary group had a higher proportion of asymptomatic cases (54% vs. 32%) and a lower relapse rate (7% vs. 52%) compared to conventional management. Treatment initiation times were significantly reduced from 3.2 to 2.2 months (p < 0.05), and the time from pathology to treatment decreased to 30 days in the multidisciplinary group versus 85 days in the conventional group. Conclusions: The multidisciplinary approach reduced waiting times for the initiation of cancer treatment, increased treatment adherence and improved clinical outcomes.
- 23 September 2025
- Published by Asociacion Latinoamericana de Torax in Respirar
- Vol. 17 (3) , 287-296
Open AccessNueva era en el abordaje del adenocarcinoma de pulmón estadio temprano: estudio observacional con seguimiento de 3 años
Background: Lung cancer is frequently diagnosed in advanced stages and is currently the leading cause of cancer-related mortality worldwide. A multidisciplinary approach is crucial to optimize diagnosis, treatment and improve patient survival. Methods: A retrospective cohort analytical study over two time periods, including patients over 18 years old with early-stage lung adenocarcinoma treated at a high-complexity oncology center in Colombia. The exposure group (2021-2023) received multidisciplinary care, while the non-exposure group (2018-2020) was managed conventionally by individual specialists. The study aimed to compare clinical outcomes and treatment times between both groups. Statistical analysis was based on the distribution of variables. Results: A total of 34 patients were included. The multidisciplinary approach enabled earlier diagnosis of lung adenocarcinoma, increasing early-stage identification from 30% to 61% between 2018 and 2022. Additionally, the multidisciplinary group had a higher proportion of asymptomatic cases (54% vs. 32%) and a lower relapse rate (7% vs. 52%) compared to conventional management. Treatment initiation times were significantly reduced from 3.2 to 2.2 months (p < 0.05), and the time from pathology to treatment decreased to 30 days in the multidisciplinary group versus 85 days in the conventional group. Conclusions: The multidisciplinary approach reduced waiting times for the initiation of cancer treatment, increased treatment adherence and improved clinical outcomes.
- Open Access
- 5 December 2024
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 11 (2) , 103-112
Respuesta profunda y duradera en cáncer de pulmón con mutación L718Q en EGFR, adquirida después de la terapia con osimertinib
Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).
- 5 December 2024
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 11 (2) , 103-112
Open AccessRespuesta profunda y duradera en cáncer de pulmón con mutación L718Q en EGFR, adquirida después de la terapia con osimertinib
Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).
- 1 December 2024
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-7
Olaparib-Induced Cutaneous Vasculitis in a Patient with Ovarian Cancer: A Case Report and Literature Review
- 1 December 2024
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-7
Olaparib-Induced Cutaneous Vasculitis in a Patient with Ovarian Cancer: A Case Report and Literature Review
- Open Access
- 30 September 2024
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 39 (3) , 350-355
Respuesta a cetuximab en carcinoma escamocelular de canal anal después de varias líneas de quimioterapia e inmunoterapia
El cáncer anal primario representa del 1% al 3% de los cánceres gastrointestinales. La histología más común es el carcinoma escamocelular, con una incidencia de 0,5 a 2 por cada 100.000 personas. El principal factor de riesgo es la infección por el virus del papiloma humano, especialmente los subtipos 16 y 18, que representan del 85% al 93% de los casos. El tratamiento y el pronóstico dependen del estadio del tumor. Los tumores localizados se pueden tratar con cirugía curativa, pero las etapas localmente avanzadas requieren una combinación de quimioterapia y radiación. Los tumores en estadio avanzado (IIIC y IV) tienen un mal pronóstico incluso con quimioterapia. En los últimos años, la inmunoterapia y las terapias dirigidas son prometedoras para mejorar la supervivencia de los pacientes con enfermedad avanzada, recurrente o difícil de tratar. Se presenta el caso de una mujer de 69 años con carcinoma escamocelular moderadamente diferenciado (T2N1M0, estadio IIIA) del canal anal que, después del tratamiento con quimiorradioterapia e inhibidores de punto de chequeo y luego de la progresión de la enfermedad, recibió tratamiento con terapia blanco (cetuximab) y logró la remisión completa de la enfermedad y una respuesta mantenida por más de 18 meses. Este caso destaca los desafíos del tratamiento del cáncer anal avanzado y los beneficios potenciales de la terapia dirigida, especialmente cetuximab, para lograr respuestas a largo plazo. Se necesitan más investigaciones a gran escala para determinar el papel de la terapia blanco y la inmunoterapia en el tratamiento de este cáncer.
- 30 September 2024
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 39 (3) , 350-355
Open AccessRespuesta a cetuximab en carcinoma escamocelular de canal anal después de varias líneas de quimioterapia e inmunoterapia
El cáncer anal primario representa del 1% al 3% de los cánceres gastrointestinales. La histología más común es el carcinoma escamocelular, con una incidencia de 0,5 a 2 por cada 100.000 personas. El principal factor de riesgo es la infección por el virus del papiloma humano, especialmente los subtipos 16 y 18, que representan del 85% al 93% de los casos. El tratamiento y el pronóstico dependen del estadio del tumor. Los tumores localizados se pueden tratar con cirugía curativa, pero las etapas localmente avanzadas requieren una combinación de quimioterapia y radiación. Los tumores en estadio avanzado (IIIC y IV) tienen un mal pronóstico incluso con quimioterapia. En los últimos años, la inmunoterapia y las terapias dirigidas son prometedoras para mejorar la supervivencia de los pacientes con enfermedad avanzada, recurrente o difícil de tratar. Se presenta el caso de una mujer de 69 años con carcinoma escamocelular moderadamente diferenciado (T2N1M0, estadio IIIA) del canal anal que, después del tratamiento con quimiorradioterapia e inhibidores de punto de chequeo y luego de la progresión de la enfermedad, recibió tratamiento con terapia blanco (cetuximab) y logró la remisión completa de la enfermedad y una respuesta mantenida por más de 18 meses. Este caso destaca los desafíos del tratamiento del cáncer anal avanzado y los beneficios potenciales de la terapia dirigida, especialmente cetuximab, para lograr respuestas a largo plazo. Se necesitan más investigaciones a gran escala para determinar el papel de la terapia blanco y la inmunoterapia en el tratamiento de este cáncer.
- 28 August 2024
- Published by Springer Nature in Die Orthopädie
- Vol. 53 (9) , 703-708
Undifferentiated sarcoma arising from fibrous dysplasia in a young adult
- 28 August 2024
- Published by Springer Nature in Die Orthopädie
- Vol. 53 (9) , 703-708
Undifferentiated sarcoma arising from fibrous dysplasia in a young adult